AGP Picks
View all

AGP Executive Report

Last update: 5 hours ago

Oral Health Equity: A University of Turku doctoral study says people with disabilities still hit major barriers to dental care, from inaccessible services and stigma to a lack of trained professionals, and calls for better practical training and stronger support for caregivers. Primary Care Access in Finland: THL reports primary healthcare waiting times worsened in 2025, with adults less often able to see a doctor within 14 days and the under-23 rule not fully met, while specialised care access improved. Menopause & Weight/Heart Risk: New analyses presented at the European Congress on Obesity link once-weekly semaglutide to weight loss and cardiovascular risk reduction across menopausal stages, including perimenopause. AI in Hospitals: Research highlights that clinical AI’s real-world rollout depends on fitting everyday workflows and reducing added workload, not just technical performance. Ovarian Cancer Research: A Karolinska Institutet postdoc wins an international grant to build an AI tool that models ovarian cancer interactions between tumor, body and environment. Disability & Work Capacity: Finland’s public-sector sickness absence data is being used to flag declining work ability and predict disability pension applications. Women’s Health Naming Update: An international consensus push backs renaming PCOS to PMOS, aiming to better reflect the condition’s metabolic and endocrine roots.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

fallback image
Jun. 1, 2026

SuperCom wins $1.8 million Norway monitoring contract

EIN Presswire

fallback image
May 4, 2026

Thai university approves ethics review of Maha Taksa astrology study

EIN Presswire

fallback image
May 29, 2026

Lower protein intake linked to weaker physical function in older adults

EIN Presswire

fallback image
May 27, 2026

Matas Group taps Revieve to expand AI beauty across the Nordics

EIN Presswire


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Clinical Artificial Intelligence Implementation in Routine Care: Real-World Operational Outcomes from a Provincial Health System in China

Clinical Artificial Intelligence Implementation in Routine Care: Real-World Operational Outcomes from a Provincial Health System in China

Stakeholder Perspectives on the Adaptability of Hospital Drug Formularies to Disease Patterns: A Modified Q-Methodology Study in Vietnam

Stakeholder Perspectives on the Adaptability of Hospital Drug Formularies to Disease Patterns: A Modified Q-Methodology Study in Vietnam

An Efficient Pharmacogenomic Assay for Psychotropic Drugs by Multiplex Fluorescence Melting Curve Analysis

An Efficient Pharmacogenomic Assay for Psychotropic Drugs by Multiplex Fluorescence Melting Curve Analysis

A Tool for Predicting Disability Pension Applications in the Finnish Public Sector: Sickness Absences as Early Indicators of Declining Work Ability

A Tool for Predicting Disability Pension Applications in the Finnish Public Sector: Sickness Absences as Early Indicators of Declining Work Ability

Subtype-Specific Response to Fractional-Mode Q-Switched Ruby Laser in Melasma: A Prospective Single-Blind Clinical Study Using Clinical and Noninvasive Imaging Assessments

Subtype-Specific Response to Fractional-Mode Q-Switched Ruby Laser in Melasma: A Prospective Single-Blind Clinical Study Using Clinical and Noninvasive Imaging Assessments


fallback image
Jun. 1, 2026

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

GlobeNewswire, Inc.

fallback image
May 30, 2026

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

GlobeNewswire, Inc.

fallback image
May 26, 2026

Public Health Command Europe Hosts 71st International Military Veterinary Exchange

DVIDS - Georgia

fallback image
May 21, 2026

Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting

GlobeNewswire, Inc.

fallback image
May 19, 2026

Herantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s disease

GlobeNewswire, Inc.

fallback image
May 13, 2026

Finland Classifies Andes Hantavirus as Public Health Risk

MENAFN

More press releases

Video Stories

YouTube video thumbnail: Hundreds of Russian Strikes Across Ukraine Kill at Least 14 People
Play
Hundreds of Russian Strikes Across Ukraine Kill at Least 14 People
YouTube video thumbnail: Russia 'Trying to Prevent Armenia's Diversification of Connectivity', Expert Says
Play
Russia 'Trying to Prevent Armenia's Diversification of Connectivity', Expert Says
Affinity Group Publishing Logo Showcase
Discover Affinity Group Publishing
YouTube video thumbnail: EU Greenlights Controversial Return Hubs in 'Strictest-Ever' New Migration Law
Play
EU Greenlights Controversial Return Hubs in 'Strictest-Ever' New Migration Law
YouTube video thumbnail: After Oil Shale: Are Magnets the Next big Business for Europe?
Play
After Oil Shale: Are Magnets the Next big Business for Europe?

Video Title

Sign up for:

Health Daily Finland

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Sign up for:

Health Daily Finland

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.